Bacterial prostatitis and prostatic fibrosis: modern view on the treatment and prophylaxis
- Authors: Zaitsev A.V1, Pushkar D.Y.1, Khodyreva L.A2, Dudareva A.A2
-
Affiliations:
- A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
- Scientific Research Institute of Healthcare Organization and Medical Management of the Department of Health of Moscow
- Issue: Vol 18, No 7 (2016)
- Pages: 14-18
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94527
- ID: 94527
Cite item
Full Text
Abstract
Treatments of chronic bacterial prostatitis (CP) remain difficult problem. Bacterial prostatitis is a disease entity diagnosed clinically and by evidence of inflammation and infection localized to the prostate. Risk factors for UTI in men include urological interventions, such as transrectal prostate biopsy. Ensuing infections after prostate biopsy, such as UTI and bacterial prostatitis, are increasing due to increasing rates of fluoroquinolone resistance. The increasing global antibiotic resistance also significantly affects management of UTI in men, and therefore calls for alternative strategies. Prostatic inflammation has been suggested to contribute to the etiology of lower urinary tract symptoms (LUTS) by inducing fibrosis. Several studies have shown that prostatic fibrosis is strongly associated with impaired urethral function and LUTS severity. Fibrosis resulting from excessive deposition of collagen is traditionally recognized as a progressive irreversible condition and an end stage of inflammatory diseases; however, there is compelling evidence in both animal and human studies to support that the development of fibrosis could potentially be a reversible process. Prostate inflammation may induce fibrotic changes in periurethral prostatic tissues, promote urethral stiffness and LUTS. Patients experiencing CP and prostate-related LUTS could benefit from anti-inflammatory therapies, especially used in combination with the currently prescribed enzyme treatment with Longidaza. Treatment results showed that Longidaza is highly effective in bacterial and abacterial CP. Longidaza addition to standard therapeutic methods significantly reduced the disease symptoms and regression of inflammatory-proliferative alterations in the prostate.
Full Text
##article.viewOnOriginalSite##About the authors
A. V Zaitsev
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
Email: msmsu@msmsu.ru
д-р мед. наук, проф. каф. урологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
D. Yu Pushkar
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
Email: msmsu@msmsu.ru
д-р мед. наук, проф., зав. каф. урологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
L. A Khodyreva
Scientific Research Institute of Healthcare Organization and Medical Management of the Department of Health of Moscow
Email: niiozmm@zdrav.mos.ru
д-р мед. наук, зав. отд. ГБУ НИИ организации здравоохранения и медицинского менеджмента 115184, Russian Federation, Moscow, ul. Bol'shaia Tatarskaia, d. 30
A. A Dudareva
Scientific Research Institute of Healthcare Organization and Medical Management of the Department of Health of Moscow
Email: niiozmm@zdrav.mos.ru
канд. мед. наук, вед. науч. сотр. ГБУ НИИ организации здравоохранения и медицинского менеджмента 115184, Russian Federation, Moscow, ul. Bol'shaia Tatarskaia, d. 30
References
- Заболеваемость взрослого населения России в 2014 году. Статистические материалы. Часть II, III. ФГБУ «Центральный научно - исследовательский институт организации и информатизации здравоохранения» Минздрава России.
- Coyene K.S., Sexton C.C., Thompson C.I. et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352-60.
- Krieger J.N, Lee S.W, Jeon J et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31 (Suppl. 1): S85-S90.
- Лоран О.Б., Пушкарь Д.Ю., Сегал А.С., Юдовский С.О. Наше понимание хронического простатита. Фарматека. 2002; 10: 69-75.
- Ulleryd P. Febrile urinary tract infection in men. Int J Antimicrob Agents 2003; 22 (Suppl 2): 89-93.
- Millan-Rodriguez F, Palou J, Bujons-Tur A et al. Acute bacterial prostatitis: twodifferent sub - categories according to a previous manipulation of the lowerurinary tract. World J Urol 2006; 24: 45-50.
- Yoon B.I, Kim S, Han D.S et al. Acute bacterial prostatitis: how to prevent andmanage chronic infection? J Infect Chemother 2012; 18: 444-50.
- Center M.M et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079.
- Loeb S et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64: 876.
- Зайцев А.В., Раснер П.И., Говоров А.В., Курджиев М.А. Современный взгляд на антибактериальную профилактику при трансректальной биопсии предстательной железы в условиях роста резистентности микрофлоры. Эффективная фармакотерапия. 2011; 1: 30-4.
- Nam R.K, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963-8.
- Loeb S, Carter H.B, Berndt S.I et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-4.
- Loeb S, van den Heuvel S, Zhu X et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-4.
- Wagenlehner F.M, van Oostrum E, Tenke P et al. Infective complications afterprostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and a prospective multinational multicentre prostatebiopsy study. Eur Urol 2013; 63: 521-7.
- Steensels D, Slabbaert K, De Wever L et al. Fluoroquinolone - resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound - guided prostatebiopsy: should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012; 18: 575-81.
- Cai T, Tiscione D, Malossini G et al. Antimicrobial prophylaxis for transrectal ultrasound - guided prostate biopsy: Fosfomycin trometamol is an attractive strategy. Poster 267, EAU16, Munich.
- Wagenlehner F et al. Urinary tract infections in men. Curr Opin Infect Dis 2014; 27: 97-101.
- Perletti G, Marras E, Wagenlehner F.M, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8: CD009071.
- Thurmond P, Jing-Hua Yang, Yedan Li et al. Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia. Korean J Urol 2015; 56 (3): 187-96. doi: 10.4111/kju.2015.56.3.187.
- Кудрявцев Ю.В., Чумаков А.М. Морфологические изменения в предстательной железе при хроническом простатите. Материалы конференции «Современные аспекты диагностики и лечения хронического простатита». Курск, 2000; с. 81-2.
- Ma J, Gharaee-Kermani M, Kunju L et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol 2012; 188 (4): 1375-81.
- Cantiello F, Cicione A, Salonia A et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology 2013; 81 (5): 1018-23.
- Wong L, Hutson P.R, Bushman W. Prostatic Inflammation Induces Fibrosis in a Mouse Model of Chronic Bacterial Infection. PloS One 2014; 9 (6): e100770.
- Wong L, Hutson P.R, Bushman W. Resolution of chronic bacterial - induced prostatic inflammation reverses established fibrosis. Prostate 2015; 75 (1): 23-32. doi: 10.1002/pros.22886.
- Пушкарь Д.Ю., Зайцев A.B., Сегал A.C. Лонгидаза в лечении хронического простатита. Урология. 2006; 6: 26-8.
- Лоран О.Б., Сегал А.С. Система комплексной оценки симптомов хронического простатита (СОС-ХП). Урология. 2001; 5.
- Ходырева Л.А., Дударева А.А., Карпов В.К. Лонгидаза в комплексной терапии хронического простатита. Эффективная фармакотерапия. Урология и нефрология. 2014; 32 (3): 24-7.
- Авдошин В.П., Андрюхин М.И., Михайликов Т.Г. Опыт применения ферментной терапии в комплексном лечении хронического простатита//Consilium Medicum. 2008; 10 (4): 114-7.
- WHO Drug Information 2015; 29: 3.
